dc.contributor.author | Alemayehu, Senait | |
dc.contributor.author | Yigezu, Amanuel | |
dc.contributor.author | Hailemariam, Damen | |
dc.contributor.author | Hailu, Alemayehu | |
dc.date.accessioned | 2021-07-15T09:14:35Z | |
dc.date.available | 2021-07-15T09:14:35Z | |
dc.date.created | 2020-07-31T21:40:06Z | |
dc.date.issued | 2020-07-27 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/11250/2764480 | |
dc.description.abstract | Background: In Ethiopia, MDR-TB has become a significant public health threat; therefore, the Ministry of Health introduced two treatment approaches for MDR-TB cases: treatment initiative center (TIC) and treatment follow-up center (TFC). TIC is where patients usually are diagnosed and start the treatment. At TFC, we follow MDR-TB patients until they completed the treatment. However, there is no evidence about the cost-effectiveness of the approaches. Therefore, this study aimed to analyze the cost-effectiveness of MDR-TB treatment in TIC and TFC.
Methods: In this study, we employed a full economic evaluation from a providers' perspective. We followed a hypothetical cohort of individuals from the age of 15 for a lifetime using a Markov model with five mutually exclusive health states. We used both primary and secondary data sources for the study. Ingredient-based costing approach was used. The costs include healthcare provider costs (recurrent and capital cost) and patient-side costs (direct and indirect). We use a human capital approach to estimate the indirect cost. The cost estimates were reported in the 2017 United States Dollar (US$), and effectiveness was measured using disability-adjusted life-years (DALYs) averted. Both costs and health benefits were discounted using a 3% discount rate. Both average and incremental cost-effectiveness ratios (ICER) were reported calculated. One-way and probabilistic sensitivity analyses were reported to determine the robustness of the estimates.
Results: The cost per HIV negative patient successfully treated for MDR-TB was USD 8,416 at TIC and USD 6,657 at TFC. The average cost-effectiveness ratio per DALY averted at TFC was USD 671 and USD 1,417 per DALY averted at TIC. The incremental cost-effectiveness ratio (ICER) of MDR-TB treatment at TIC was USD 1,641 per DALYs averted.
Conclusion: This study indicates that the treatment of MDR-TB at both TIC and TFC are cost-effective interventions compared with the willingness to pay threshold of three-times the GDP per capita in Ethiopia. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | PLoS | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright the authors | en_US |
dc.source.articlenumber | e0235820 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1371/journal.pone.0235820 | |
dc.identifier.cristin | 1821169 | |
dc.source.journal | PLOS ONE | en_US |
dc.identifier.citation | PLOS ONE. 2020, 15 (7), e0235820. | en_US |
dc.source.volume | 15 | en_US |
dc.source.issue | 7 | en_US |